TNFRSF8 and classic Hodgkin lymphoma: Immunohistochemistry, flow and mass cytometry, and gene expression profiling techniques have provided a better understanding of the TME in cHL, and have contributed to new treatment approaches, e.g., anti-CD30 antibody and programmed cell death protein 1 inhibitors (PD-1 inhibitors).